Melanoma Clinical Trial

Clinical Trial Finder Melanoma Trials

Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

See Locations Near You

Summary

The purpose of this clinical research study is to compare the best overall response rate (BORR)(as per modified WHO criteria) in patients with previously treated, therapy-refractory, or -intolerant, Stage III (unresectable) or Stage IV melanoma receiving ipilimumab doses of 0.3, 3, and 10 mg/kg. The safety of this product will also be evaluated.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients with previously treated, therapy-refractory or -intolerant, Stage III (unresectable) or Stage IV melanoma

Study is for people with:

Melanoma

Phase:

Phase 2

Estimated Enrollment:

210

Study ID:

NCT00289640

Recruitment Status:

Completed

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 62 Locations for this study

See Locations Near You

Arizona Cancer Center
Tucson Arizona, 85724, United States
Wilshire Oncology Medical Group Inc
Laverne California, 91750, United States
Scripps Cancer Center
San Diego California, 92121, United States
The Angeles Clinic And Research Institution
Santa Monica California, 90404, United States
Yale University School Of Medicine
New Haven Connecticut, 06520, United States
Baptist Cancer Institute
Jacksonville Florida, 32207, United States
Mount Sinai Comprehensive Cancer Center
Miami Beach Florida, 33140, United States
Md Anderson Cancer Center Orlando
Orlando Florida, 32806, United States
Palm Beach Cancer Institute
West Palm Beach Florida, 33401, United States
Oncology Specialists, Sc
Park Ridge Illinois, 60068, United States
American Health Network
Indianapolis Indiana, 46202, United States
University Of Louisville
Louisville Kentucky, 40202, United States
Harry And Jeanette Weinberg Cancer Inst At Franklin Square
Baltimore Maryland, 21237, United States
Hubert H. Humphrey Cancer Center
Robbinsdale Minnesota, 55422, United States
Ellis Fischel Cancer Center
Columbia Missouri, 65203, United States
St Joseph Oncology Inc
St Joseph Missouri, 64507, United States
Washington University School Of Medicine
St. Louis Missouri, 63110, United States
Memorial Sloan Kettering Cancer Center
New York New York, 10021, United States
Presbyterian Hospital
Charlotte North Carolina, 28204, United States
The Christ Hospital Cancer Center Research
Cincinnati Ohio, 45219, United States
Cleveland Clinic
Cleveland Ohio, 44195, United States
Providence Portland Medical Center
Portland Oregon, 97213, United States
Cancer Centers Of The Carolinas
Greenville South Carolina, 29615, United States
Center For Oncology Research & Treatment, P.A.
Dallas Texas, 75230, United States
Mary Crowley Medical Research Center
Dallas Texas, 75246, United States
Local Institution
Newcastle New South Wales, 2300, Australia
Local Institution
Brisbane Queensland, 4101, Australia
Local Institution
Heidelberg Victoria, 3084, Australia
Local Institution
Wodonga Victoria, 3690, Australia
Local Institution
Brussels , 1090, Belgium
Local Institution
Bruxelles , 1070, Belgium
Local Institution
Bruxelles , 1200, Belgium
Local Institution
Centro-Porto Alegre Rio Grande Do Sul, 90020, Brazil
Local Institution
Porto Alegre Rio Grande Do Sul, 90610, Brazil
Local Institution
Jau Sao Paulo, 17210, Brazil
Local Institution
Sao Paulo , 01509, Brazil
Local Institution
Calgary Alberta, T2N 4, Canada
Local Institution
Edmonton Alberta, T6G 1, Canada
Local Institution
Kingston Ontario, K7L 5, Canada
Local Institution
Olomouc , 775 2, Czech Republic
Local Institution
Praha , 128 0, Czech Republic
Local Institution
Brest Cedex, 29200, France
Local Institution
Clermont Ferrand , 63058, France
Local Institution
Lyon Cedex 08 , 69373, France
Local Institution
Lyon , 69288, France
Local Institution
Marseille Cedex 09 , 13009, France
Local Institution
Paris , 75010, France
Local Institution
Rennes , 35042, France
Local Institution
Toulouse , 31059, France
Local Institution
Vandoeuvre Les Nancy , 54511, France
Local Institution
Berlin , 12200, Germany
Local Institution
Essen , 45122, Germany
Local Institution
Heidelberg , 69115, Germany
Local Institution
Jena , 07740, Germany
Local Institution
Kiel , 24105, Germany
Local Institution
Mannheim , 68169, Germany
Local Institution
Wurzburg , 97080, Germany
Local Institution
Pécs , 7624, Hungary
Local Institution
Johannesburg Gauteng, 2199, South Africa
Local Institution
Pretoria Gauteng, 0041, South Africa
Local Institution
Pretoria Gauteng, 0181, South Africa
Local Institution
Cape Town Western Cape, 7506, South Africa
Load More

How clear is this clinincal trial information?

Study is for people with:

Melanoma

Phase:

Phase 2

Estimated Enrollment:

210

Study ID:

NCT00289640

Recruitment Status:

Completed

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
SurvivorNet’s Guide To Clinical Trials: What Are They And Are They Right for You?
Clinical Trials Can be Life-Saving for Some
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider